J Clin Med Res

Journal of Clinical Medicine Research, ISSN 1918-3003 print, 1918-3011 online, Open Access

Article copyright, the authors; Journal compilation copyright, J Clin Med Res and Elmer Press Inc

Journal website http://www.jocmr.org

Original Article

Volume 9, Number 3, March 2017, pages 183-187

Prognostic Impact of the Tumor Marker CA 15-3 in Patients With Breast Cancer and Bone Metastases Treated With Palliative Radiotherapy

Figure 1. Actuarial Kaplan-Meier survival curves for 89 patients with bone metastases from breast cancer stratified by serum CA 15-3 level (median 17.6 for lowest quartile (< 32.5 kIE/L) versus 14.7 months for intermediate levels and 6.9 months for highest quartile (> 208 kIE/L), P = 0.002), log-rank test.

**Table 1.** Patient Characteristics Before Radiotherapy (RT) and Survival Outcomes (n = 118)
Parameter	n	%	Median survival, months	P-value
^aInformation not available in all patients. ^bP-value calculated over all strata. ECOG PS: Eastern Cooperative Oncology Group performance status; LDH: lactate dehydrogenase; ALP: alkaline phosphatase; CRP: C-reactive protein.
Estrogen receptor (ER) positive	91	77	15.6
Estrogen receptor (ER) negative	27	23	5.8	0.004
HER2 positive^a	20	18	14.4
HER2 negative^a	90	82	12.4	0.65
Triple negative^a	22	20	5.5
ER positive HER2 negative^a	68	62	15.5
ER negative HER2 positive^a	5	5	11.4
ER and HER2 positive^a	15	14	15.9	0.007^b
Metastases at first diagnosis^a	17	15	6.9
Metachronous metastatic disease^a	98	85	14.7	0.13
Interval from metastatic disease to RT ≤ 1 month^a	32	28	17.6
Interval from metastatic disease to RT 2 - 6 months^a	24	21	13.9
Interval from metastatic disease to RT 7 - 12 months^a	14	12	7.5
Interval from metastatic disease to RT 13 - 59 months^a	35	30	9.0
Interval from metastatic disease to RT ≥ 60 months^a	10	9	9.0	0.02^b
No extra-skeletal visceral metastases	57	48	22.9
One site of visceral metastases, e.g. lung(s)	43	36	8.2
More than one site of visceral metastases	18	15	5.1	0.0001^b
Liver metastases	36	31	7.3	0.0001
Lung metastases	38	32	7.3	0.004
Pleural metastases/effusion	19	16	3.9	0.0001
Brain metastases	4	3	3.4	0.0001
ECOG PS 0	32	27	27.3
ECOG PS 1	38	32	15.6
ECOG PS 2	32	27	10.3
ECOG PS 3 - 4	16	14	3.1	0.0001^b
Received no previous RT	26	22	14.9
One previous course	51	43	16.9
At least two previous courses	41	35	9.0	0.01^b
Serum albumin normal^a	94	84	15.5
Serum albumin low^a	18	16	5.1	0.001
Serum LDH normal^a	45	45	27.0
Serum LDH high^a	56	55	6.9	0.0001
Serum ALP normal^a	47	45	21.1
Serum ALP high^a	58	55	9.0	0.0001
Serum CRP normal^a	55	50	22.9
Serum CRP high (≤ 30)^a	29	26	12.7
Serum CRP high (31 - 60)^a	13	12	5.8
Serum CRP high (> 60)^a	14	13	5.0	0.0001^b
Hemoglobin normal^a	80	71	15.9
Hemoglobin low^a	33	29	8.2	0.004
Received blood transfusion before RT	9	8	9.0	0.01
CA 15-3 normal^a	14	16	36.2
CA 15-3 high^a	75	84	12.2	0.007

Table 1. Patient Characteristics Before Radiotherapy (RT) and Survival Outcomes (n = 118)

Parameter

Median survival, months

P-value

^aInformation not available in all patients. ^bP-value calculated over all strata. ECOG PS: Eastern Cooperative Oncology Group performance status; LDH: lactate dehydrogenase; ALP: alkaline phosphatase; CRP: C-reactive protein.

Estrogen receptor (ER) positive

15.6

Estrogen receptor (ER) negative

5.8

0.004

HER2 positive^a

14.4

HER2 negative^a

12.4

0.65

Triple negative^a

5.5

ER positive HER2 negative^a

15.5

ER negative HER2 positive^a

11.4

ER and HER2 positive^a

15.9

0.007^b

Metastases at first diagnosis^a

6.9

Metachronous metastatic disease^a

14.7

0.13

Interval from metastatic disease to RT ≤ 1 month^a

17.6

Interval from metastatic disease to RT 2 - 6 months^a

13.9

Interval from metastatic disease to RT 7 - 12 months^a

7.5

Interval from metastatic disease to RT 13 - 59 months^a

9.0

Interval from metastatic disease to RT ≥ 60 months^a

9.0

0.02^b

No extra-skeletal visceral metastases

22.9

One site of visceral metastases, e.g. lung(s)

8.2

More than one site of visceral metastases

5.1

0.0001^b

Liver metastases

7.3

0.0001

Lung metastases

7.3

0.004

Pleural metastases/effusion

3.9

0.0001

Brain metastases

3.4

0.0001

ECOG PS 0

27.3

ECOG PS 1

15.6

ECOG PS 2

10.3

ECOG PS 3 - 4

3.1

0.0001^b

Received no previous RT

14.9

One previous course

16.9

At least two previous courses

9.0

0.01^b

Serum albumin normal^a

15.5

Serum albumin low^a

5.1

0.001

Serum LDH normal^a

27.0

Serum LDH high^a

6.9

0.0001

Serum ALP normal^a

21.1

Serum ALP high^a

9.0

0.0001

Serum CRP normal^a

22.9

Serum CRP high (≤ 30)^a

12.7

Serum CRP high (31 - 60)^a

5.8

Serum CRP high (> 60)^a

5.0

0.0001^b

Hemoglobin normal^a

15.9

Hemoglobin low^a

8.2

0.004

Received blood transfusion before RT

9.0

0.01

CA 15-3 normal^a

36.2

CA 15-3 high^a

12.2

0.007